Phenylketonuria, commonly called PKU, is a genetic condition where your body cannot properly break down an amino acid called phenylalanine. This amino acid is found in nearly all protein-containing foods. Without treatment, phenylalanine builds up in the blood and brain, causing serious neurological damage. PKU affects roughly 6 out of every 100,000 newborns worldwide, and every baby born in the United States is screened for it within the first 48 hours of life.
How PKU Works in the Body
Your liver normally produces an enzyme that converts phenylalanine into another amino acid called tyrosine. In people with PKU, the gene responsible for making this enzyme carries mutations that reduce or eliminate its activity. Without this conversion happening properly, two things go wrong at once.
First, phenylalanine accumulates in the blood and gets converted into toxic byproducts, including phenylacetic acid and phenylpyruvic acid. These compounds are harmful to brain development, particularly in infants and young children. Second, because phenylalanine isn’t being converted to tyrosine, the body runs low on tyrosine. This matters because tyrosine is the building block for several critical brain chemicals, including dopamine and norepinephrine. It’s also needed to produce thyroid hormone and melanin, the pigment that gives skin and hair their color.
Genetics and Inheritance
PKU follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy of the PAH gene from both parents to develop the condition. The PAH gene sits on chromosome 12 and contains the instructions for building the enzyme that breaks down phenylalanine. If you inherit only one defective copy, you’re a carrier with no symptoms. When two carriers have a child together, there’s a 25% chance the baby will have PKU, a 50% chance the baby will be a carrier, and a 25% chance the baby won’t carry the gene at all.
Rates vary significantly by region. Turkey has the highest reported prevalence at about 38 per 100,000 newborns, while some Southeast Asian countries see rates below 1 per 100,000. In the United States, estimates from large screening programs have ranged from about 5 to 10 per 100,000.
How PKU Is Detected
Nearly all cases of PKU are caught through newborn screening before any symptoms appear. A small blood sample is taken from a heel prick after the baby is 24 hours old but before leaving the hospital. The blood is tested for elevated phenylalanine levels. If the result comes back abnormal, parents are contacted quickly, sometimes that same day, and referred to a metabolic specialist for confirmatory testing. A blood phenylalanine level above 120 micromoles per liter signals a problem, and levels above 360 micromoles per liter require lifelong treatment.
This early detection is one of the great success stories of public health screening. Before routine newborn testing began in the 1960s, PKU was typically diagnosed only after a child showed signs of developmental delay, by which point significant brain damage had already occurred.
What Happens Without Treatment
Untreated PKU causes progressive and largely irreversible damage to the nervous system. The most serious consequence is intellectual disability, which can be severe. Other neurological effects include seizures, tremor, problems with balance and coordination, behavioral disturbances, and impairment of both sensory and motor function. Some individuals develop what’s known as phenylketonuric encephalopathy, a pattern of brain damage that shows up as difficulties with memory, verbal fluency, and spatial reasoning.
There are also noticeable physical signs. Because excess phenylalanine disrupts melanin production, people with untreated PKU often have unusually fair skin, light hair, and blue eyes compared to their family members. The toxic byproducts of phenylalanine metabolism also produce a distinctive musty or mousy body odor.
The PKU Diet
The cornerstone of PKU management is a strict low-phenylalanine diet that begins in infancy and continues for life. Since phenylalanine is present in virtually all protein, this means avoiding or heavily restricting a long list of foods: meat, chicken, fish, eggs, cheese, nuts, seeds, wheat, oats, barley, soy, lentils, and legumes. Even some meat substitutes and the artificial sweetener aspartame (which contains phenylalanine) are off-limits.
Cutting out this much protein would normally lead to malnutrition, so people with PKU rely on specialized medical formulas. These are amino acid mixtures that provide all the protein building blocks the body needs, minus the phenylalanine. For someone with classic PKU, these formulas supply at least 75% of their daily protein needs. They also provide tyrosine, which the body can’t make on its own when the enzyme isn’t working.
The target for blood phenylalanine in the United States is 1 to 6 mg/dL for infants and young children, with 1 to 10 mg/dL considered acceptable for older individuals. Reaching these targets requires regular blood monitoring, careful meal planning, and a level of dietary discipline that many people find genuinely challenging to sustain over a lifetime.
Long-Term Cognitive Effects
Even with early treatment, PKU can affect cognitive function, particularly when dietary control slips during adolescence and adulthood. Research on early-treated adults with PKU has found that impairments tend to show up in complex thinking tasks: reasoning, planning, monitoring multiple pieces of information at once. Processing speed is also consistently slower across different types of mental tasks. The good news is that learning ability and memory tend to be well preserved.
The critical finding from long-term studies is that metabolic control during adolescence and adulthood matters significantly. Adults with PKU who maintained lower phenylalanine levels performed normally on cognitive tests, while those with higher levels showed measurable impairments. This underscores why current guidelines recommend maintaining diet for life, a shift from earlier decades when some doctors told families they could relax the diet after childhood.
Medications for PKU
Two medications are now available for certain people with PKU. The first, approved in 2007, is an oral medication that works by boosting whatever residual enzyme activity a person still has. It’s essentially a synthetic version of the natural cofactor the enzyme needs to function. Not everyone responds to it. Before starting treatment, patients undergo a trial period to see if their phenylalanine levels drop. Those who respond can often relax their diet somewhat, though most still need some dietary restriction.
The second medication, approved in 2018, takes a completely different approach. It’s an injected enzyme substitute that breaks down phenylalanine through an alternative chemical pathway, bypassing the deficient enzyme entirely. It’s currently approved only for adults whose blood phenylalanine remains above 600 micromoles per liter despite existing management. For those who qualify, it can dramatically lower phenylalanine levels and allow a much less restrictive diet.
PKU and Pregnancy
Women with PKU face a specific and serious risk during pregnancy. High phenylalanine in the mother’s blood crosses the placenta and is toxic to the developing fetus, even if the baby doesn’t have PKU. This is called maternal PKU syndrome, and it can cause microcephaly (an abnormally small head), heart defects, and developmental problems in the baby. The fetus is exposed to phenylalanine concentrations even higher than what’s in the mother’s blood, making tight dietary control before and throughout pregnancy essential. Women with PKU who are planning a pregnancy are advised to get their phenylalanine levels into the target range before conception and maintain strict control for the full duration.